Olutasidenib 单药或联合阿扎胞苷治疗 IDH1 突变急性髓系白血病和骨髓增生异常综合征:1/2 期试验的 1 期结果
这项 1/2 期多中心开放标签试验评估了 olutasidenib 单药或联合阿扎胞苷在 IDH1 突变急性髓系白血病或骨髓增生异常综合征患者中的安全性、药代动力学、药效学和临床活性。78 例患者接受治疗,未报告剂量限制性毒性,150 mg 每日两次被确定为推荐 2 期剂量;复发或难治性急性髓系白血病患者中单药组总缓解率 41%,联合组 46%。
要点
- 未报告剂量限制性毒性,基于安全性、药代动力学、药效学和临床活性确定 150 mg 每日两次为推荐 2 期剂量。
- 复发或难治性急性髓系白血病患者总缓解率:单药组 41%(95% CI 21-64),联合阿扎胞苷组 46%(95% CI 27-67)。
- 初治急性髓系白血病患者总缓解率:单药组 25%(95% CI 1-81),联合阿扎胞苷组 77%(95% CI 46-95)。
核心结论
- Olutasidenib 单药或联合阿扎胞苷耐受性良好,在 IDH1 突变急性髓系白血病患者中显示出有意义的临床活性。
- 1 期研究结果为在多种髓系恶性肿瘤患者人群中继续评估 olutasidenib 提供了依据。
研究设计与样本
- 1/2 期、多中心、开放标签临床试验,在美国、澳大利亚、法国和西班牙的 18 个研究中心入组患者。
- 纳入年龄 18 岁及以上、携带 IDH1 突变的急性髓系白血病或中危、高危或极高危骨髓增生异常综合征患者,其他关键入选标准包括 ECOG 体能状态 0-2 分且肝肾功能充足。
- Olutasidenib 口服给药,剂量为 150 mg 每日一次、150 mg 每日两次和 300 mg 每日一次;阿扎胞苷 75 mg/m2 皮下或静脉给药,每日一次,连续 7 天,休息 21 天。
- 2016 年 8 月 8 日至 2018 年 11 月 14 日入组,78 例患者接受 olutasidenib 单药(n=32)或联合阿扎胞苷(n=46)治疗;数据截止日期为 2019 年 10 月 2 日。
- 主要结局为剂量限制性毒性和最大耐受剂量、最大评估剂量及 olutasidenib 的推荐 2 期剂量。
主要发现
- 单药组中位随访 8.3 个月(IQR 3.1-13.3),联合组中位随访 10.1 个月(IQR 4.2-15.3)。
- 剂量递增队列中未报告剂量限制性毒性,基于安全性、药代动力学、药效学和临床活性,150 mg 每日两次被确定为推荐 2 期剂量。
- 单药组最常见的(≥20%)3-4 级治疗中出现的不良事件为血小板减少(9/32,28%)、发热性中性粒细胞减少(7/32,22%)和贫血(7/32,22%);联合组为血小板减少(19/46,41%)、发热性中性粒细胞减少(13/46,28%)、中性粒细胞减少(13/46,28%)和贫血(9/46,20%)。
- 单药组 11/32(34%)患者死亡,联合组 9/46(20%)患者死亡,最常见死因为疾病进展(单药组 3/32,9%;联合组 4/46,9%);无死亡被认为与研究药物相关。
- 复发或难治性急性髓系白血病患者中,单药组总缓解率为 41%(95% CI 21-64;9/22),联合组为 46%(95% CI 27-67;12/26);初治急性髓系白血病患者中,单药组总缓解率为 25%(95% CI 1-81;1/4),联合组为 77%(95% CI 46-95;10/13)。
关键数值与推荐
- Olutasidenib 推荐 2 期剂量为 150 mg 每日两次。
- 阿扎胞苷剂量为 75 mg/m2,皮下或静脉给药,每日一次,连续 7 天,休息 21 天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of olutasidenib, as monotherapy or in combination with azacitidine, in patients with acute myeloid leukaemia or myelodysplastic syndrome, harbouring mutant IDH1. METHODS: In this phase 1/2, multicentre, open-label clinical trial, we enrolled patients aged 18 years or older with acute myeloid leukaemia or intermediate, high, or very high risk myelodysplastic syndrome harbouring mutant IDH1 at 18 study sites in the USA, Australia, France, and Spain. Other key eligibility criteria included Eastern Cooperative Oncology Group performance status 0-2 with adequate liver and renal function. The primary outcomes were dose-limiting toxicities and the maximum tolerated dose, maximum evaluated dose, and the recommended phase 2 dose of olutasidenib. Olutasidenib was administered orally in doses of 150 mg once daily, 150 mg twice per day, and 300 mg once daily. Azacitidine (75 mg/m2) was administered subcutaneously or intravenously daily for 7 days on, 21 days off. The study was ongoing at the data cutoff (Oct 2, 2019) and is registered with ClinicalTrials.gov, NCT02719574. FINDINGS: Patients were enrolled between Aug 8, 2016, and Nov 14, 2018. 78 patients received olutasidenib as monotherapy (n=32) or in combination with azacitidine (n=46). The median follow-up was 8·3 months (IQR 3·1-13·3) for monotherapy and 10·1 months (4·2-15·3) for combination therapy. 16 (50%) of 32 patients in the monotherapy group and 24 (52%) of 46 patients in the combination therapy group were women. Most patients were White (26 [81%] for monotherapy and 31 [67%] for combination therapy). No dose-limiting toxicities were reported in the dose-escalation cohorts and 150 mg twice per day was declared the recommended phase 2 dose on the basis of safety, pharmacokinetics and pharmacodynamics, and clinical activity. The most common (≥20%) grade 3-4 treatment-emergent adverse events with monotherapy were thrombocytopenia (nine [28%] of 32 patients), febrile neutropenia (seven [22%] of 32), and anaemia (seven [22%] of 32); and with combination therapy were thrombocytopenia (19 [41%] of 46), febrile neutropenia (13 [28%] of 46), neutropenia (13 [28%] of 46), and anaemia (nine [20%] of 46). 11 (34%) of 32 patients in the monotherapy group and nine (20%) of 46 patients in the combination therapy group died (most commonly from disease progression [three (9%) of 32 and four (9%) of 46]). No deaths were considered study-drug related. For patients with relapsed or refractory acute myeloid leukaemia, 41% (95% CI 21-64; nine of 22) receiving monotherapy and 46% (27-67; 12 of 26) receiving combination therapy had an overall response. For treatment-naive patients with acute myeloid leukaemia, 25% (1-81; one of four) receiving monotherapy and 77% (46-95; ten of 13) receiving combination therapy had an overall response. INTERPRETATION: Olutasidenib, with or without azacitidine, was well tolerated and showed meaningful clinical activity in patients with IDH1-mutated acute myeloid leukaemia. The results of this phase 1 study provide rationale for the continued evaluation of olutasidenib in multiple patient populations with myeloid malignancies. FUNDING: Forma Therapeutics.
引用
- Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2022. PMID: 36370742. doi:10.1016/S2352-3026(22)00292-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。